Abstract:Abstract Background Nucleotide-specific 5-hydroxymethylcytosine (5hmC) remains understudied in pediatric central nervous system (CNS) tumors. 5hmC is abundant in the brain, and alterations to 5hmC in adult CNS tumors have been reported. However, traditional approaches to measure DNA methylation do not distinguish between 5-methylcytosine (5mC) and its oxidized counterpart 5hmC, including those used to build CNS tumor DNA methylation classification systems. We measured 5hmC and 5mC epigenome-wide at nucleotide resolution in glioma, ependymoma, and embryonal tumors from children, as well as control pediatric brain tissues using tandem bisulfite and oxidative bisulfite treatments followed by hybridization to the Illumina Methylation EPIC Array that interrogates over 860,000 CpG loci. Results Linear mixed effects models adjusted for age and sex tested the CpG-specific differences in 5hmC between tumor and non-tumor samples, as well as between tumor subtypes. Results from model-based clustering of tumors was used to test the relation of cluster membership with patient survival through multivariable Cox proportional hazards regression. We also assessed the robustness of multiple epigenetic CNS tumor classification methods to 5mC-specific data in both pediatric and adult CNS tumors. Compared to non-tumor samples, tumors were hypohydroxymethylated across the epigenome and tumor 5hmC localized to regulatory elements crucial to cell identity, including transcription factor binding sites and super-enhancers. Differentially hydroxymethylated loci among tumor subtypes tended to be hypermethylated and disproportionally found in CTCF binding sites and genes related to posttranscriptional RNA regulation, such as DICER1 . Model-based clustering results indicated that patients with low 5hmC patterns have poorer overall survival and increased risk of recurrence. Our results suggest 5mC-specific data from OxBS-treated samples impacts methylation-based tumor classification systems giving new opportunities for further refinement of classifiers for both pediatric and adult tumors. Conclusions We identified that 5hmC localizes to super-enhancers, and genes commonly implicated in pediatric CNS tumors were differentially hypohydroxymethylated. We demonstrated that distinguishing methylation and hydroxymethylation is critical in identifying tumor-related epigenetic changes. These results have implications for patient prognostication, considerations of epigenetic therapy in CNS tumors, and for emerging molecular neuropathology classification approaches.

Pan-cancer Landscape of Aberrant DNA Methylation Across Childhood Cancers: Molecular Characteristics and Clinical Relevance

A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors

Comparative Pan-Cancer DNA Methylation Analysis Reveals Cancer Common and Specific Patterns.

High-frequency aberrantly methylated targets in pancreatic adenocarcinoma identified via global DNA methylation analysis using methylCap-seq

Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma

The Identification of Specific Methylation Patterns across Different Cancers

Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

Targeting DNA Methylation Machinery in Pediatric Solid Tumors

Integrative Analysis of Multi-Omics Identified the Prognostic Biomarkers in Acute Myelogenous Leukemia

Pan-Cancer Genome-Wide DNA Methylation Analyses Revealed That Hypermethylation Influences 3D Architecture and Gene Expression Dysregulation in HOXA Locus During Carcinogenesis of Cancers

Exploring Epigenetic Biomarkers of Universal Specificities and Commonalities among Pan-Cancer Cohorts in the Cancer Genome Atlas.

Pan-cancer Genome and Transcriptome Analyses of 1,699 Paediatric Leukaemias and Solid Tumours.

Pan-precancer and cancer DNA methylation profiles revealed significant tissue specificity of interrupted biological processes in tumorigenesis.

Pediatric Pan-Central Nervous System Tumor Methylome Analyses Reveal Immune-Related LncRNAs

Comparison of Different Normalization Assumptions for Analyses of Dna Methylation Data from the Cancer Genome

DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker

Modeling Prostate Cancer Oncogenesis Through Developmental Alterations in Zebrafish

Identification of the Differential DNA Methylation Markers among Cancers

Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications.

Pan-cancer Analysis of DNA Methyltransferase Family with Potential Implications in Prognosis and Immunology in Human Cancer

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer